Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (66 patients) or never received BRAF inhibitor (63 patients). The combination of vemurafenib and cobimetinib was deemed safe and tolerable. Confirmed objective responses were seen in 15% of vemurafenib progressed patients and median progression-free survival was 2.8 months (95% CI 2·6–3·4). Confirmed objective responses were seen in 87% of patients who had never received BRAF inhibitor, including 10% with complete response. Median progression-free survival was 13.7 months (95% CI 10·1–17·5). The majority of patients had BRAF V600E mutation. Post-hoc sequencing of 94 tumor samples indicated seven tumors with a mutation other than BRAF V600E.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6966
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Cobimetinib,Vemurafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25037139
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cobimetinib | Sensitivity | true |
| Vemurafenib | Sensitivity | true |